Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

19.47% 19.30% 12.03% 11.20%
Piotroski F-Score
7 7 6 7
ROA
6.77% 6.99% 4.02% 3.99%
ROIC
10.30% 10.69% 5.53% 5.62%
Return on Tangible Assets
26.12% 25.03% 11.34% 11.31%
Average Days of Receivables
56.92 54.19 59.33 58.33
Free Cash Flow per Share
5.45 6.65 5.55 6.45
Free Cash Flow
259.20 311.38 261.82 292.53
Capital Expenditures
(29.84) (27.46) (31.40) (35.62)
Other line items
Cash ROIC
12.55% 14.19% 11.58% 13.12%
Accounts Receivable Turnover
6.31 6.47 6.36 6.49
Accounts Payable Turnover
8.47 9.60 9.26 10.82
Inventory Turnover
1.54 1.57 1.63 1.66
Average Days of Payables
40.63 33.17 34.10 37.13
Days of Inventory on Hand
221.40 218.78 204.64 202.14
Tax Rate
(0.23) (0.23) (0.24) (0.26)
Research and Development Expense of Revenue
4.92% 4.83% 4.48% 4.42%
Selling, General and Administrative Expense of Revenue
32.68% 33.12% 33.16% 33.33%
Share Based Compensation of Revenue
2.41% 2.40% 2.54% 2.50%
Interest Coverage
9.47 10.49 5.46 5.36
Operating CF/Net income
1.72 1.93 3.01 3.41
Depreciation/Fixed assets
0.43 0.41 0.38 0.37
Capex/Depreciation
(0.24) (0.23) (0.27) (0.31)
Revenue per Share
27.90 28.17 28.28 29.81
Operating CF per Share
6.07 7.24 6.22 7.23
Capex per Share
(0.63) (0.59) (0.67) (0.79)
Capex to Sales
0.02 0.02 0.02 0.03

Fold the line items

Columns are period end dates